CpG 1018®佐剂增强小鼠针对百日咳博德特菌的Tdap免疫应答
研究评估CpG 1018®佐剂提升Tdap疫苗抗体应答及抵抗百日咳博德特菌攻击的能力。小鼠模型中,含CpG 1018的Tdap对百日咳毒素、丝状血凝素及全菌抗体应答增加,1/20人用剂量Tdap加CpG 1018改善下呼吸道保护与细菌清除,并促进对PRN-菌株清除,诱导更多细菌调理和Th1型抗体(IgG2a、IgG2b)。
要点
- CpG 1018加入Tdap可增加对PT、FHA及全菌的抗体应答。
- 1/20人用剂量Tdap加CpG 1018改善下呼吸道保护和细菌清除。
- Tdap与Tdap+CpG 1018均能促进PRN-菌株清除。
核心结论
- 研究显示在Tdap中加入CpG 1018相比传统仅含铝佐剂的Tdap可改善免疫原性和针对百日咳博德特菌的保护。
研究设计与样本
- 小鼠模型研究,评估系列滴定剂量的Tdap疫苗以识别CpG 1018的佐剂能力,并进行百日咳博德特菌鼻内攻击研究。
主要发现
- 含CpG 1018使对百日咳毒素、丝状血凝素或全菌的抗体应答增加。
- 在鼻内攻击研究中,1/20人用剂量Tdap加CpG 1018改善下呼吸道保护和细菌清除。
- Tdap与Tdap+CpG 1018均能促进不表达百日咳杆菌粘附素(PRN-)菌株的清除。
- 抗体功能表型显示含CpG 1018诱导更多细菌调理和Th1表型抗体(IgG2a和IgG2b)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bordetella pertussis is the causative agent of whooping cough (pertussis), a severe respiratory disease that can be fatal, particularly in infants. Despite high vaccine coverage, pertussis remains a problem because the currently used DTaP and Tdap vaccines do not completely prevent infection or transmission. It is well established that the alum adjuvant is a potential weakness of the acellular vaccines because the immunity provided by it is short-term. We aimed to evaluate the potential of CpG 1018® adjuvant to improve antibody responses and enhance protection against B. pertussis challenge in a murine model. A titrated range of Tdap vaccine doses were evaluated in order to best identify the adjuvant capability of CpG 1018. Antibody responses to pertussis toxin (PT), filamentous hemagglutinin (FHA), or the whole bacterium were increased due to the inclusion of CpG 1018. In B. pertussis intranasal challenge studies, we observed improved protection and bacterial clearance from the lower respiratory tract due to adding CpG 1018 to 1/20th the human dose of Tdap. Further, we determined that Tdap and Tdap + CpG 1018 were both capable of facilitating clearance of strains that do not express pertactin (PRN-), which are rising in prevalence. Functional phenotyping of antibodies revealed that the inclusion of CpG 1018 induced more bacterial opsonization and antibodies of the Th1 phenotype (IgG2a and IgG2b). This study demonstrates the potential of adding CpG 1018 to Tdap to improve immunogenicity and protection against B. pertussis compared to the conventional, alum-only adjuvanted Tdap vaccine.
引用
- DeJong MA, Wolf MA, Bitzer GJ, et al. CpG 1018® adjuvant enhances Tdap immune responses against Bordetella pertussis in mice. Vaccine. 2022. PMID: 35927132. doi:10.1016/j.vaccine.2022.07.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。